Campath-1 Abs ‘in the bag’ for hematological malignancies: the Cape Town experience

References

• Apperley JF, Mauro FR, Goldman JM et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br Haematol 1988;69:239–45.
   PubMed Web of Science ®Google Scholar
• Glucksberg H, Storb R, Fefer A et al. Clinical manifestations ofgraft vs host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974;18:295.
   PubMed Web of Science ®Google Scholar
• Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl 7 Med 1991;324: 667–74.
   Google Scholar
• Weiden PL, Sullivan KM, Flournoy N et al. Antileukemic effectof chronic graft vs host disease: contribution to improved survival after allogeneic marrow transplantation. New Engl Med 1981;304:1529–33.
   PubMed Web of Science ®Google Scholar
• Enright H, Davies SM, De For T et al. Relapse after non-T-celldepleted allogeneic bone marrow transplantation for chronic myelogenous leukaemia: early transplantation, use of an un-related donor and chronic grafts vs. host disease are protective. Blood 1996;88:714–20.
   Google Scholar
• Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukaemia without mye-loablative therapy. Blood 1997;89:4531–6.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Bacigalupo A, Labopin et al. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. [European Group for Blood and Marrow Transplanta-tion (EBMT).]. Br 7 Haematol 1996;95:715–23.
   Google Scholar
• Waldmann H, Hale G, Cividalli G et al. Elimination of graft vshost disease by in vitro T-cell depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984;1:483–6.
   Google Scholar
• Maraninchi D, Gluckman E, Blaise D et al. Impact of T cell depletion on outcome of allogeneic bone marrow transplanta-tion for standard risk leukemias. Lancet 1987;ii:75–8.
   Google Scholar
• Apperley JF, Jones L, Hale G et al. Bone marrow transplantationfor patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1986;1:53–66.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT et al. Proposals for theclassification of the acute leukaemias. French-American-British (FAB) co-operative group. Br 7 Haematol 1976;33:451–8.
   PubMed Web of Science ®Google Scholar
• Coltman CA, Dahlberg S, Jones SE et al. CHOP is curative inthirty percent of patients with large cell lymphoma. A twelve-year Southwest Oncology Group Study follow-up. In: Skarin AT, editor. Update on treatment for diffitse large-cell lymphoma. New York: John Wiley and Sons, Inc, 1986: 71–7.
   Google Scholar
• Raje N, Powles R, Kulkarni S et al. A comparison of vincristineand doxorubicin infusional chemotherapy with methylpredni-solone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br y Haematol 1997;97:153–60.
   PubMed Web of Science ®Google Scholar
• Novitzky N, Thomas V, Hale G, Waldman H. Ex vivo depletion of T-cells from BM grafts with CAMPATH 1G in acute leukemia: graft vs host disease and graft vs. leukemia effect Transplantation 1999;67:620–6.
   PubMed Web of Science ®Google Scholar
• Novitzky N, Rubinstein R, Hallett JM et al. Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: a therapeutic strategy. Trans-plantation 2000;69:1358–63.
   Google Scholar
• Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34± cell determination by flow cytometry. Hematother 1996;5:213–26.
   PubMedGoogle Scholar
• Hale G, Xia M-Q, Tighe HP et al. The CAMPATH-1 antigen(Cdw 52). Tissue Antigens 1990;35:118–27.
   PubMed Web of Science ®Google Scholar
• Hale G, Waldmann H. Control of graft-versus-host disease andgraft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 1994;13:597–611.
   PubMed Web of Science ®Google Scholar
• Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukaemia after bone marrow transplantation: separation of grafts vs. leukaemia responses from graft vs. host disease. Blood 1995;86:1261–8.
   Google Scholar
• Frassoni F', Labopin M, Gluckman E et al. Are patients with acute leukaemia, alive and well 2 years post bone marrow transplantation cured? A European survey. [Acute Leukaemia Working Party of the European Group for Bone Marrow Transplantation (EBMT).]. Leukemia 1994;8: 924–8.
   Google Scholar
• Novitzky N, Davison GM, Hale G, Waldmann H. Immune reconstitution at 6 months following T-cell depleted hemato-poietic stem cell transplantation is predictive for treatment outcome. Transplantation 2002;74:1551–9.
   PubMed Web of Science ®Google Scholar
• Roux E, Helg C, Dumont-Girard F et al. Analysis of T-cell repopulation after allogeneic marrow transplantation: significant differences between recipients of T-cell depleted and unmani-pulated grafts. Blood 1996;87:3984–92.
   PubMed Web of Science ®Google Scholar
• Williams RJ, Clarke E, Blair A, et al. Impact on T-cell depletionand CD34± cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G. Cytother-apy 2000;2:5–14.
   PubMed Web of Science ®Google Scholar
• Robello P, Cwynarski K, Vaughese M et al. Pharmacokinetics ofCAMPATH-1 H in BMT patients. Cytotherapy 2001;3:261–7.
   PubMed Web of Science ®Google Scholar
• Alyea EP, Soiffer RJ, Canning C et al. Toxicity and efficacy of defined doses of CD4± donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998;91:3671–80.
   PubMed Web of Science ®Google Scholar
• Atkinson K, Horowitz MM, Gale RP et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990;75:2459–64.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, MacDonald D, Hale G et al. T-cell depletion with Campath-1H 'in the bag' for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br 7 Haematol 2003;12: 109–18.
   Google Scholar
• Nagler A, Slavin S, Varadi G et al. Allogeneic peripheral bloodstem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000;25:1021–8.
   PubMed Web of Science ®Google Scholar
• Slavin S, Nagler A, Naparstek E et al. Non-myeloablative stemcell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytor-eduction for the treatment of malignant and non-malignant hematologic disease. Blood 1998;91:756–63.
   PubMed Web of Science ®Google Scholar
• Mohty M, Fegueux N, Exbrayat C et al. Enhanced graft-versus-tumor effect following dose-reduced conditioning and allo-geneic transplantation for refractory lymphoid malignancies after high-dose therapy. Bone Marrow Transplant 2001;28:335–9.
   PubMed Web of Science ®Google Scholar